Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin

Eur Heart J. 2009 Aug;30(15):1831-6. doi: 10.1093/eurheartj/ehp186. Epub 2009 May 24.

Abstract

Aims We examined the specific effects of unfractionated heparin and bivalirudin on thrombin-inducible platelet PAR-1 in patients undergoing percutaneous coronary intervention (PCI). Methods and results To simulate in vivo conditions that may precipitate a bleeding event, we added thrombin in vitro to blood samples from 89 patients who had been randomly assigned to receive heparin or bivalirudin for elective PCI and examined thrombin-inducible PAR-1 expression. Thrombin-inducible cleavage of PAR-1 was inhibited by heparin, but not affected by bivalirudin (P = 0.0001). Further, PAR-1 internalization was more effectively inhibited by heparin than bivalirudin (P = 0.002). Conclusion Heparin has stronger inhibitory effects on thrombin-dependent PAR-1 cleavage and internalization, thus providing a biological explanation for lower clinical bleeding rates with bivalirudin.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary* / methods
  • Anticoagulants / therapeutic use*
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Heparin / therapeutic use*
  • Hirudins
  • Humans
  • Male
  • Middle Aged
  • P-Selectin / metabolism
  • Peptide Fragments / therapeutic use*
  • Platelet Activation / drug effects*
  • Receptor, PAR-1 / metabolism*
  • Recombinant Proteins / therapeutic use
  • Thrombin / antagonists & inhibitors*
  • Thrombin / metabolism

Substances

  • Anticoagulants
  • Fibrin Fibrinogen Degradation Products
  • Hirudins
  • P-Selectin
  • Peptide Fragments
  • Receptor, PAR-1
  • Recombinant Proteins
  • fibrin fragment D
  • Heparin
  • Thrombin
  • bivalirudin